Axcella (NASDAQ: AXLA) Activates Clinical Sites For EMMPOWER Study of AXA1665 in OHE
Axcella (NASDAQ: AXLA) has announced the activation of initial clinical study sites and patient screening for the global phase 2 clinical study of AXA1665. AXA1665 is Axcella’s multi-target oral drug candidate for reducing the risk of recurrent overt hepatic encephalopathy. OHE is a severe condition with a devastating impact Andres Duarte-Rojo, the principal study investigator, said, “OHE is a condition that has devastating consequences for patients and families and places…